| 臺大學術典藏 |
2020-04-10T12:51:12Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen Y.-C.; Ou D.-L.; Chiun Hsu; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Ou D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.; Chen L.-T.; Lin Z.-Z.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Chiun Hsu; Lin Y.-L.; Shen Y.-C.;Li C.-P.;Yen C.-J.;Chiun Hsu;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Chiun Hsu; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
|
Cheng A.-L.; Lim S.T.; Suh C.; Kwong Y.-L.; Kim W.S.; Chng W.-J.; Kim S.J.; Chiun Hsu; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T.; Lee J.; Intragumtornchai T. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan
|
Chang Y.-T.; Chang M.-C.; Huang K.-W.; Tung C.-C.; Chiun Hsu; Wong J.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.;Chen I.-C.;Chiun Hsu;Chang S.-Y.;Chien S.-F.;Chen Y.-C.;Hu F.-C.;Yang J.C.-H.;Cheng A.-L.;Yeh K.-H.; Kao H.-F.; Chen I.-C.; Chiun Hsu; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:08Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Chiun Hsu; Chen C.-H.; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:08Z |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou D.-L.;Lee B.-S.;Lin L.-I.;Liou J.-Y.;Liao S.-C.;Chiun Hsu;Cheng A.-L.; Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:08Z |
Reply
|
Chiun Hsu; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:07Z |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study
|
Van Cutsem E.; Li C.-P.; Nowara E.; Aprile G.; Moore M.; Federowicz I.; Van Laethem J.-L.; Chiun Hsu; Tham C.K.; Stemmer S.M.; Lipp R.; Zeaiter A.; Fittipaldo A.; Csutor Z.; Klughammer B.; Meng X.; Ciuleanu T. |
| 臺大學術典藏 |
2020-04-10T12:51:07Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Chiun Hsu; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou D.-L.;Shyue S.-K.;Lin L.-I.;Feng Z.-R.;Liou J.-Y.;Fan H.-H.;Lee B.-S.;Chiun Hsu;Cheng A.-L.Ann-Lii; Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Chiun Hsu; Cheng A.-L.Ann-Lii |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis
|
Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; Ou D.-L.; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; Chiun Hsu; Lin L.-I.; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Chiun Hsu;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Chiun Hsu; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
Chen L.-T.; Shih T.T.F.; Liu T.W.; Chiun Hsu; Liang P.-C.;Ch’Ang H.-J.;Chiun Hsu;Chen L.-T.;Shih T.T.F.;Liu T.W.; Liang P.-C.; Ch’ang H.-J. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Chiun Hsu;Chen B.-B.;Chen C.-H.;Ho M.-C.;Cheng J.C.-H.;Kokudo N.;Murakami T.;Yeo W.;Seong J.;Jia J.-D.;Han K.-H.;Cheng A.-L.; Chiun Hsu; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:04Z |
Cough with bile
|
Chang C.-C.; Chiun Hsu; Liu K.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:04Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Shih T.T.-F.; Cheng A.-L.; Hsu C.-H.; Chiun Hsu; Liang P.-C.; Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W. |
| 臺大學術典藏 |
2020-04-10T12:51:04Z |
A decade of changes in preferences for life-sustaining treatments among terminally ill patients with cancer
|
Chang C.-S.; Sung Y.-C.; Hsieh C.-I.; Chang S.-Y.; Liu L.N.; Chiang M.-C.; Tang S.T.;Liu T.-W.;Wen F.-H.;Chiun Hsu;Chang Y.-H.;Chang C.-S.;Sung Y.-C.;Hsieh C.-I.;Chang S.-Y.;Liu L.N.;Chiang M.-C.; Tang S.T.; Liu T.-W.; Wen F.-H.; Chiun Hsu; Chang Y.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.;Kuo T.-C.;Wu H.;Guo J.-C.;Chiun Hsu;Hsu C.-H.;Tien Y.-W.;Yeh K.-H.;Cheng A.-L.;Kuo S.-H.; Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Chiun Hsu; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chen L.-T.; Huang S.-F.; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Chiun Hsu; Chiang N.-J.; Chiang N.-J.;Chiun Hsu;Chen J.-S.;Tsou H.-H.;Shen Y.-Y.;Chao Y.;Chen M.-H.;Yeh T.-S.;Shan Y.-S.;Huang S.-F.;Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Chiun Hsu; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:02Z |
Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy
|
Chang P.-L.; Lin W.-Y.; Chiun Hsu; Chang H.-Y.; Ou D.-L.; Lin Y.-Z.; Lin Y.-Z.;Ou D.-L.;Chang H.-Y.;Lin W.-Y.;Chiun Hsu;Chang P.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:02Z |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
Melero I.; Dastani H.B.; Tang H.; Neely J.; El-Khoueiry A.B.;Sangro B.;Yau T.;Crocenzi T.S.;Kudo M.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Trojan J.;Welling T.H.;3Rd, Meyer T.;Kang Y.-K.;Yeo W.;Chopra A.;Anderson J.;Dela Cruz C.;Lang L.;Neely J.;Tang H.;Dastani H.B.;Melero I.; El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.;Tan C.-T.;Chen C.-W.;Ou D.-L.;Cheng A.-L.;Chiun Hsu; Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
|
Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Chiun Hsu; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.;Lin Y.-Y.;Hsu C.-L.;Lin Y.-Y.;Chen C.-W.;Yu J.-S.;Miaw S.-C.;Hsu P.-N.;Cheng A.-L.;Chiun Hsu; Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis
|
Xu C.;Chen Y.-P.;Du X.-J.;Liu J.-Q.;Huang C.-L.;Chen L.;Zhou G.-Q.;Li W.-F.;Mao Y.-P.;Chiun Hsu;Liu Q.;Lin A.-H.;Tang L.-L.;Sun Y.;Ma J.; Xu C.; Chen Y.-P.; Du X.-J.; Liu J.-Q.; Huang C.-L.; Chen L.; Zhou G.-Q.; Li W.-F.; Mao Y.-P.; Chiun Hsu; Liu Q.; Lin A.-H.; Tang L.-L.; Sun Y.; Ma J. |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Taiwan Cooperative Oncology Group; Chiun Hsu; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; Cheng A.-L.; Tsou H.-H.; Yang H.-C.; Yang H.-C.;Tsou H.-H.;Pei S.-N.;Chang C.-S.;Chen J.-H.;Yao M.;Lin S.-J.;Lin J.;Yuan Q.;Xia N.;Liu T.-W.;Chen P.-J.;Cheng A.-L.;Chiun Hsu;Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2020-04-10T12:50:59Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.;Yang H.-C.;Hsiao C.-F.;Hsiung C.A.;Liu T.-W.;Chuang M.-H.;Wu H.-Y.;Hsu Y.-T.;Tsui C.-W.;Chen P.-J.;Cheng A.-L.;Chiun Hsu;Taiwan Cooperative Oncology Group; Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; Cheng A.-L.; Chiun Hsu; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2020-04-10T12:50:58Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.;Guo J.-C.;Chiun Hsu;Kuo S.-H.;Tien Y.-W.;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; Guo J.-C.; Chiun Hsu; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-09T09:32:39Z |
Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Chih‐Hung Hsu;Ann‐Lii Cheng;Zhong‐Zhe Lin;Yin‐Chung Shen;Li‐Chun Lu;Chiun Hsu;Tsung‐Hao Liu;Yu‐Yun Shao; Yu‐Yun Shao; Tsung‐Hao Liu; Chiun Hsu; Li‐Chun Lu; Yin‐Chung Shen; Zhong‐Zhe Lin; Ann‐Lii Cheng; Chih‐Hung Hsu |
| 臺大學術典藏 |
2020-04-07T08:52:19Z |
Group Report Contest Enhances Problem-Based Learning
|
Chiun Hsu; Shan-Chwen Chang; Fen-Yu Tseng; Jeng-Yi Shieh;Chien-An Yao;Chiun Hsu;Shan-Chwen Chang;Fen-Yu Tseng; JENG-YI SHIEH; Chien-An Yao |
| 臺大學術典藏 |
2020 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T.; Tsou H.-H.; CHIUN HSU; Yen C.-J.; Yang S.-H.; Chen M.-H.; Chiang N.-J. |
| 臺大學術典藏 |
2020 |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Shen W.-C.; CHIUN HSU; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T.; Hsiao H.-H.; Yang S.-H.; Tsai K.K.; Hsiao C.-F.; Chiang N.-J. |
| 臺大學術典藏 |
2020 |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU |
| 臺大學術典藏 |
2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; CHIUN HSU |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. |
| 臺大學術典藏 |
2019 |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2019 |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; CHIUN HSU; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
